Janus Henderson Group PLC grew its stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 15.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,339,254 shares of the company's stock after acquiring an additional 576,059 shares during the quarter. Janus Henderson Group PLC owned about 13.12% of Lexeo Therapeutics worth $28,508,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Barclays PLC boosted its position in Lexeo Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 50,210 shares of the company's stock valued at $454,000 after buying an additional 31,057 shares during the last quarter. Wellington Management Group LLP boosted its position in Lexeo Therapeutics by 48.3% in the fourth quarter. Wellington Management Group LLP now owns 76,981 shares of the company's stock valued at $507,000 after buying an additional 25,089 shares during the last quarter. Rhumbline Advisers boosted its position in Lexeo Therapeutics by 19.6% in the fourth quarter. Rhumbline Advisers now owns 25,197 shares of the company's stock valued at $166,000 after buying an additional 4,127 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Lexeo Therapeutics by 135.6% in the third quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company's stock valued at $93,000 after buying an additional 5,915 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in Lexeo Therapeutics in the fourth quarter valued at approximately $117,000. Institutional investors and hedge funds own 60.67% of the company's stock.
Lexeo Therapeutics Stock Performance
Lexeo Therapeutics stock traded up $0.03 during mid-day trading on Tuesday, hitting $3.32. The company had a trading volume of 71,425 shares, compared to its average volume of 480,751. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $110.21 million, a price-to-earnings ratio of -1.04 and a beta of 1.27. The company's fifty day moving average is $3.08 and its 200-day moving average is $4.89. Lexeo Therapeutics, Inc. has a 12-month low of $1.45 and a 12-month high of $19.50.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.19). Equities research analysts predict that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the company. HC Wainwright dropped their target price on Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday. Chardan Capital dropped their target price on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Leerink Partners lowered their price objective on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research report on Monday, March 24th. Finally, Royal Bank of Canada lowered their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 25th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $20.20.
View Our Latest Stock Analysis on Lexeo Therapeutics
Lexeo Therapeutics Company Profile
(
Free Report)
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Further Reading
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
